![Andrew Cunningham](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Andrew Cunningham
Technik-/Wissenschafts-/F&E-Leiter bei
CALCIMEDICA, INC.
Profil
Andrew Cunningham is Senior Vice President-Clinical Development at CalciMedica, Inc. since 2023.
Formerly, Dr. Cunningham was Head-Neurodegenerative at Taysha Gene Therapies, Inc. from 2021 to 2022, Vice President-Clinical Development at Reata Pharmaceuticals, Inc. from 2018 to 2021, Medical Director at Takeda Pharmaceutical Co., Ltd. from 2017 to 2018, and Medical Director at Genzyme Therapeutics Ltd. from 2012 to 2014.
Dr. Cunningham completed undergraduate and MBA degrees at University College Dublin.
Aktive Positionen von Andrew Cunningham
| Unternehmen | Position | Beginn |
|---|---|---|
| CALCIMEDICA, INC. | Technik-/Wissenschafts-/F&E-Leiter | 23.05.2023 |
Ehemalige bekannte Positionen von Andrew Cunningham
| Unternehmen | Position | Ende |
|---|---|---|
| TAYSHA GENE THERAPIES, INC. | Corporate Officer/Principal | 01.04.2022 |
| REATA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.02.2021 |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Corporate Officer/Principal | 01.07.2018 |
Genzyme Therapeutics Ltd.
 Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Corporate Officer/Principal | 01.06.2014 |
Ausbildung von Andrew Cunningham
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
44
Beziehungen ersten Grades
6
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
Reata Pharmaceuticals, Inc.
 Reata Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics which regulates cellular metabolism and inflammation in serious neurologic diseases | Health Technology |
Takeda Pharmaceutical Co., Ltd.
 Takeda Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Engages in the research, development, manufacturing and marketing of pharmaceutical products | Health Technology |
University College Dublin
 University College Dublin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Health Technology |
Taysha Gene Therapies, Inc.
 Taysha Gene Therapies, Inc. BiotechnologyHealth Technology Develops and commercializes adeno-associated viruses-based gene therapies for the treatment of monogenic diseases of the central nervous system | Health Technology |
CalciMedica, Inc.
 CalciMedica, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
